Tralokinumab is a medication being studied for its effectiveness in treating moderate-to-severe atopic hand eczema. It is used as a monotherapy, which means it is given alone without any other medications. The goal of using tralokinumab in this trial is to see how well it can reduce the severity and spread of eczema on the hands. This medication is administered every two weeks to participants who are candidates for systemic therapy, meaning they need treatment that affects the entire body rather than just the skin.

Atopic Dermatitis – Atopic dermatitis is a chronic skin condition characterized by dry, itchy, and inflamed skin. It often begins in childhood and can persist into adulthood. The skin may become red, swollen, and cracked, and in severe cases, it can lead to thickened skin due to constant scratching. Flare-ups can occur periodically, often triggered by environmental factors or stress. The condition is associated with a malfunction in the skin barrier and immune system, leading to increased sensitivity to irritants and allergens. It is commonly found in individuals with a family history of allergies or asthma.

Atopic Hand Eczema – Atopic hand eczema is a form of eczema that specifically affects the hands, causing them to become dry, itchy, and inflamed. It is often seen in individuals with a history of atopic dermatitis or other allergic conditions. The skin on the hands may crack, blister, or peel, leading to discomfort and difficulty in performing daily tasks. This condition can be exacerbated by frequent hand washing, exposure to irritants, or changes in weather. It tends to be persistent and may require ongoing management to control symptoms. The condition can significantly impact the quality of life due to its visibility and the functional importance of the hands.